Eli Lilly recently announced encouraging Phase 1 results for its ovarian cancer treatment using a folate receptor alpha ...

Although as of this week the stock has declined by more than 4% since the start of the year, there's little reason to believe ...

Financial Stability: Eli Lilly's balance sheet is more robust, with debt making up only 4% of equity, considerably less than ...